United States Premenstrual Syndrome Treatment Market to Reach US$ 730.58 Million by 2033

The United States Premenstrual Syndrome (PMS) Treatment Market is experiencing steady growth as awareness of women’s health issues increases and new treatment solutions emerge. Premenstrual syndrome affects millions of women across the country, prompting greater demand for effective therapies that address both physical and emotional symptoms.

According to analysis by Renub Research, the U.S. Premenstrual Syndrome Treatment Market is expected to expand from US$ 517.31 million in 2024 to US$ 730.58 million by 2033, registering a compound annual growth rate (CAGR) of 3.91% between 2025 and 2033. The market’s growth is largely fueled by increasing awareness of PMS symptoms, improved access to healthcare, and advances in pharmaceutical and wellness treatments.

As healthcare providers and policymakers continue to emphasize women’s reproductive health, PMS treatment solutions are becoming more accessible and diversified across the United States.

United States Premenstrual Syndrome Treatment Market Outlook

Premenstrual syndrome refers to a combination of emotional, physical, and behavioral symptoms that occur during the luteal phase of the menstrual cycle. Common symptoms include mood swings, irritability, bloating, fatigue, headaches, and abdominal cramps.

These symptoms can significantly affect daily activities, work productivity, and interpersonal relationships. As a result, effective treatment strategies have become essential for improving quality of life among affected individuals.

Treatment approaches for PMS range from lifestyle adjustments—such as exercise, dietary changes, and stress management—to pharmacological therapies including analgesics, antidepressants, and hormonal medications.

In recent years, the United States has seen increased public awareness regarding PMS and related conditions such as premenstrual dysphoric disorder (PMDD). Social media discussions, healthcare campaigns, and educational resources have helped reduce stigma surrounding menstrual health.

Additionally, digital health platforms and telemedicine services are enabling more women to seek professional medical guidance and share treatment experiences. These developments have strengthened recognition of PMS as a legitimate medical condition and expanded access to treatment options nationwide.

Key Growth Drivers in the U.S. Premenstrual Syndrome Treatment Market

Rising Awareness and Diagnosis of PMS

One of the primary factors driving market growth is the increasing awareness and diagnosis of PMS among women in the United States. Healthcare organizations, public health campaigns, and wellness initiatives have played a major role in educating women about reproductive health issues.

As awareness increases, more women are seeking professional medical advice for symptoms such as mood swings, fatigue, and menstrual pain. Early diagnosis allows healthcare providers to recommend appropriate treatments ranging from over-the-counter pain relievers to prescription medications.

Social media platforms and digital health communities have also contributed to spreading awareness about PMS symptoms and available treatment options.

According to the Office on Women’s Health, over 90% of women experience some form of premenstrual symptoms during their reproductive years, highlighting the significant potential demand for PMS treatment solutions.

Expansion of Women’s Healthcare Infrastructure

The expansion of women’s healthcare services across the United States is another key factor supporting market growth. Investments in gynecology clinics, specialized wellness centers, and hospital departments focused on hormonal health have improved access to diagnosis and treatment.

Healthcare providers are increasingly adopting integrated treatment approaches that combine hormonal therapies, antidepressants, and nutritional supplements to address PMS symptoms more effectively.

Telemedicine services have also transformed the accessibility of reproductive healthcare. Women can now consult medical professionals remotely, receive prescriptions online, and manage symptoms more conveniently.

Insurance coverage for women’s health services has further reduced financial barriers associated with ongoing PMS management.

In February 2025, Opill® launched a multi-state college tour aimed at promoting reproductive health awareness. Through its “Level The Court” initiative, the program supported education and accessibility for birth control options, highlighting broader efforts to improve women’s healthcare access.

Growing Demand for Natural and Non-Hormonal Therapies

Another emerging trend in the U.S. PMS treatment market is the increasing preference for non-hormonal and natural treatment options. Many women seek alternatives to hormonal medications due to concerns about potential side effects.

Nutraceutical products such as calcium, magnesium, and vitamin B6 supplements are gaining popularity as supportive therapies for PMS symptom management.

Herbal remedies—including chasteberry and evening primrose oil—are also widely used for their perceived benefits in hormonal balance and mood stabilization.

Lifestyle-based treatments such as yoga, stress management programs, and dietary planning are increasingly integrated into PMS care strategies.

In January 2025, the U.S. Food and Drug Administration approved Journavx (suzetrigine), a non-opioid oral analgesic developed by Vertex Pharmaceuticals. The drug targets peripheral sodium channels and offers a new pain management option that may support treatment of PMS-related pain symptoms.

The growing demand for plant-based and clean-label health products is encouraging pharmaceutical and wellness companies to expand their offerings in the natural therapy segment.

Challenges in the U.S. PMS Treatment Market

Lack of Standardized Diagnostic Criteria

Despite increasing awareness, one of the major challenges in the PMS treatment market is the absence of standardized diagnostic criteria.

Symptoms of PMS vary significantly among individuals and often overlap with other medical conditions such as anxiety disorders or thyroid imbalances. As a result, diagnosis can be inconsistent.

Many women continue to self-diagnose PMS and rely on over-the-counter medications without seeking professional medical advice. Differences in diagnostic practices among healthcare providers further contribute to inconsistent treatment outcomes.

Additionally, awareness remains limited in underserved communities where access to gynecological care is restricted.

Improving diagnostic tools and expanding public health education initiatives will be essential to ensure accurate diagnosis and effective management of PMS.

Side Effects and Limited Efficacy of Certain Medications

Another key challenge facing the market is the potential side effects associated with some PMS medications.

Selective serotonin reuptake inhibitors (SSRIs), commonly prescribed for severe PMS and PMDD, may cause side effects such as nausea, sleep disturbances, and reduced libido.

Hormonal therapies can also produce unwanted effects including weight gain, mood changes, and irregular menstrual bleeding.

These side effects often lead to treatment discontinuation or reluctance to begin medication therapy.

To address these challenges, pharmaceutical companies are focusing on developing targeted therapies with improved safety profiles and enhanced tolerability.

Advancements in drug formulations—such as extended-release medications and combination therapies—are expected to improve treatment adherence and overall outcomes.

Segment Insights in the U.S. PMS Treatment Market

Analgesics Segment

Analgesics play a crucial role in managing physical PMS symptoms such as cramps, headaches, and muscle pain. Nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen and naproxen are widely used due to their rapid action and anti-inflammatory properties.

The increasing popularity of self-care solutions and over-the-counter medications continues to support growth in this segment.

Antidepressants Segment

Antidepressants are commonly prescribed to treat mood-related PMS symptoms including anxiety, depression, and irritability.

Selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine and sertraline are frequently used to stabilize mood and improve emotional well-being.

Growing awareness of mental health issues has contributed to greater acceptance of antidepressant therapies for PMS management.

Prescription Treatment Segment

Prescription treatments—including hormonal contraceptives, antidepressants, and diuretics—are widely used for managing moderate to severe PMS symptoms.

Advancements in diagnostic techniques and increased physician consultations have strengthened demand for prescription medications.

Telehealth services are also making it easier for patients to obtain prescriptions and follow treatment plans.

Online Pharmacy Distribution Channel

Online pharmacies are rapidly emerging as a key distribution channel for PMS treatments in the United States.

E-commerce platforms offer convenience, privacy, and competitive pricing, encouraging many women to purchase medications and supplements online.

Digital health tools such as symptom-tracking applications are also helping patients manage treatment plans more effectively.

Regional Insights Across Key U.S. States

California

California represents one of the most prominent regional markets for PMS treatment due to its advanced healthcare infrastructure and strong focus on women’s wellness.

Cities such as Los Angeles and San Francisco host numerous gynecology clinics and wellness centers offering advanced PMS treatment options.

The state’s growing interest in holistic and natural therapies also drives demand for herbal supplements and alternative treatments.

New Jersey

New Jersey’s PMS treatment market benefits from its proximity to major pharmaceutical and biotechnology hubs.

Hospitals and clinics across the state increasingly provide hormonal therapies, mental health support, and nutritional counseling to address PMS symptoms.

Strong insurance coverage and healthcare accessibility further support market growth.

Washington

Washington State’s emphasis on preventive healthcare and personalized treatment approaches contributes to strong demand for PMS therapies.

Healthcare providers frequently combine medication with lifestyle interventions such as dietary guidance and stress management.

The widespread use of telehealth services also ensures access to PMS treatment solutions in both urban and rural areas.

Competitive Landscape

The U.S. PMS treatment market includes several major pharmaceutical companies that focus on developing innovative treatments for women’s health conditions.

Key companies operating in the market include:

• AbbVie Inc.

• BASF SE

• Bayer AG

• Dr. Reddy’s Laboratories Ltd.

• Eli Lilly and Company

• GlaxoSmithKline Plc.

• H. Lundbeck A/S

• Pfizer Inc.

• SHIONOGI & Co. Ltd.

These companies are investing in research, drug development, and strategic collaborations to expand their portfolios and improve treatment outcomes for PMS patients.

Final Thoughts

The United States Premenstrual Syndrome Treatment Market is poised for steady growth as awareness of women’s health continues to increase and treatment options evolve.

With the market expected to rise from US$ 517.31 million in 2024 to US$ 730.58 million by 2033, advancements in healthcare infrastructure, pharmaceutical innovation, and digital health platforms will play a critical role in shaping future market dynamics.

As stigma surrounding menstrual health decreases and more women seek medical support, the demand for effective PMS treatments is expected to grow. Continued research, improved diagnostic practices, and patient-centered treatment approaches will further strengthen the market in the coming years.